Lipoic Acid Rejuvenates Aging Intestinal Stem Cells Through Paneth Cell Signaling
α-Lipoic acid declines in aged human intestines and supplementation reverses stem cell aging via Paneth cell mTOR inhibition.
Summary
Researchers found that α-lipoic acid (ALA) levels drop significantly in the small intestines of older humans and mice due to reduced expression of the biosynthetic enzyme LIAS. Supplementing ALA in human intestinal organoids and old mice restored intestinal stem cell (ISC) proliferation, differentiation, and mitochondrial health. Critically, ALA's anti-aging effects required intact Paneth cells — the specialized niche cells adjacent to ISCs. ALA inhibited mTOR signaling in Paneth cells, boosting secretion of the pro-ISC molecule cyclic ADP ribose (cADPR) and reducing the Wnt inhibitor Notum. These findings identify ALA as a promising therapeutic candidate for age-related intestinal diseases in humans.
Detailed Summary
The intestinal epithelium undergoes continuous renewal driven by intestinal stem cells (ISCs), but aging progressively impairs this regenerative capacity, elevating risks of malnutrition, chronic inflammation, and colorectal cancer in elderly populations. Prior work in Drosophila had identified α-lipoic acid (ALA) as a potential rejuvenating compound for gut stem cells, but whether this translates to humans — whose intestinal architecture includes the mammalian-exclusive Paneth cells — remained unknown.
Using jejunal biopsies collected during Roux-en-Y gastric reconstruction surgeries, researchers demonstrated by LC-ESI-MS/MS that ALA levels are significantly lower in old compared to young human small intestines. This decline correlated with reduced expression of lipoic acid synthetase (LIAS) and six additional ALA biosynthesis pathway genes at both the protein and mRNA levels, a pattern also recapitulated in aged mice.
To study functional consequences, human intestinal organoids were derived from young and old donors. Old organoids showed fewer budding structures, reduced EdU-positive proliferating cells, and fewer Olfm4-positive ISCs. ALA supplementation at 100 µM rescued all these deficits in old organoids without perturbing young organoids. In aged mice given 100 mg/kg/day ALA for three months, SOX9⁺ and EdU⁺ ISC numbers recovered, mitochondrial cristae integrity improved, and gut barrier proteins (Occludin, Claudin-1) were restored.
The mechanistic centerpiece of the study is the role of Paneth cells. ALA reduced the proportion of atypical (dysfunctional) Paneth cells in aged organoids and mice. Critically, when Paneth cells were ablated — either genetically or with diphtheria toxin in mouse models — ALA lost its ability to rescue ISC aging phenotypes. Using conditioned media experiments, the team showed that ALA treatment of Paneth cells increased secretion of cyclic ADP ribose (cADPR), a calcium-mobilizing signaling molecule, and decreased secretion of Notum, a Wnt pathway inhibitor. Both changes together promoted ISC proliferation and function. Rapamycin, a canonical mTOR inhibitor, phenocopied ALA's effects on Paneth cells, placing mTOR inhibition upstream of cADPR and Notum regulation.
These findings establish a Paneth cell-dependent paracrine mechanism through which ALA counteracts ISC aging in human tissue, offering a translationally relevant therapeutic avenue. The convergence on mTOR also links ALA's effects to one of the most established pro-longevity pathways known.
Key Findings
- ALA levels and LIAS enzyme expression are significantly reduced in old human and mouse small intestines.
- ALA supplementation restores ISC proliferation, organoid formation, and mitochondrial integrity in aged tissue.
- ALA's anti-aging effects on ISCs are entirely dependent on the presence of functional Paneth cells.
- ALA inhibits mTOR in Paneth cells, increasing cADPR secretion and decreasing Notum to enhance ISC function.
- Rapamycin mimics ALA's Paneth cell effects, linking ALA to the mTOR longevity pathway.
Methodology
The study combined LC-ESI-MS/MS metabolomics, immunohistochemistry, and RT-qPCR in human jejunal biopsies (young vs. old donors) with human and mouse intestinal organoid cultures and in vivo mouse ALA supplementation (100 mg/kg/day, 3 months). Paneth cell necessity was confirmed via genetic and diphtheria toxin-mediated ablation models, and mechanistic signaling was probed through conditioned media and pharmacological mTOR inhibition.
Study Limitations
The human tissue samples were opportunistically collected from gastric cancer surgical patients, which may not fully represent healthy aging populations. The study did not include female mice or human female donors in sufficient numbers to assess sex-specific effects. Optimal ALA dosing and long-term safety for intestinal indications in humans have not yet been established.
Enjoyed this summary?
Get the latest longevity research delivered to your inbox every week.